Effects of low-dose marine oils on intimal hyperplasia in autologous vein grafts

Eicosapentaenoic acid inhibits cell growth and triacylglycerol secretion in McA-RH7777 rat hepatoma cultures

“…There is, however, ample precedent for this finding in other cell types: Marine n-3 PUFAs have been found to depress growth and growth-related phenomena in other neoplasms [53][54][55][56][57], in vascular cells [58][59][60], and even in cultured normal human skin fibroblasts [61]. Although the mechanisms of growth inhibition are not known, changes in prostanoid metabolism in themselves are not thought to be responsible [58,59], nor is it likely that free-radical-mediated cell injury accounts for the anti-proliferative properties of EPA. In our system, careful handling of fatty acids during preparation of fatty acid: BSA complexes and the presence of FBS-supplied antioxidants in basal medium were sufficient to prevent detectable peroxidation of EPA.…”

“…We are hesitant to extrapolate the behaviour of hepatoma cells given an EPA-predominant fatty acid environment in culture to hepatic function in intact subjects for whom maximal plasma levels of EPA, as well as its proportion of the plasma NEFA pool, are considerably lower. Nevertheless, we are concerned that antiproliferative effects of n -3 PUFAs have been observed in vivo [58,59], and that fish-oil treatment is finding its way into paediatric use [75]. Until the effects of fishoil n -3 PUFAs on hepatocyte proliferation are better understood, perhaps they should be administered cautiously in clinical situations where continued hepatic growth or regeneration is desirable.…”

Large animal model of vein grafts intimal hyperplasia: A systematic review

“…Different models were designed to study the development of IH. This included using femoral vein–femoral artery interposition in 23 studies ( in situ or reversed), 14,17,18,20,23–25,30,32–38,40,42,51,52,55,56,58,60 jugular vein–carotid artery interposition grafts in 12 studies, 12,16,19,29,31,41,46,49,50,54,57,59 jugular vein–femoral artery interposition graft in 7 studies, 6–9,11,39,48 cephalic vein–femoral artery interposition graft in 2 studies, 47,53 femoral vein–carotid interposition in 2 studies, 21,22 saphenous vein–femoral artery interposition model in 2 studies, 15,27 Jugular vein to both the carotid and femoral arteries in 1 study, 13 jugular vein to carotid artery and femoral vein to femoral artery in 1 study ( in situ or reversed), 26 and 1 study used different types of venous and arterial interposition models. 10 The saphenous vein end to side between the LAD and aorta was used in 2 studies, 43,45 and 2 studies utilized a femoropopliteal-saphenous vein end to the side model.…”

“…There was no sufficient information regarding sequence generation or random housing. All the other fields showed that the risk of bias was low or unclear with some minor concern of high risk of bias regarding baseline characteristics in 3 studies, 9,13,101 selective reporting in 3 studies, 9,13,60 incomplete outcome data in 1 study, 60 and other sources of bias in 3 studies 9,52,92…”

“…Different models were designed to study the development of IH. This included using femoral vein-femoral artery interposition in 23 studies (in situ or reversed), 14,17,18,20,[23][24][25]30,[32][33][34][35][36][37][38]40,42,51,52,55,56,58,60 jugular vein-carotid artery interposition grafts in 12 studies, 12,16,19,29,31,41,46,49,50,54,57,59 jugular vein-femoral artery interposition graft in 7 studies, [6][7][8][9]11,39,48 cephalic vein-femoral artery interposition graft in 2 studies, 47,53 femoral vein-carotid interposition in 2 studies, 21,22 saphenous vein-femoral artery interposition model in 2 studies, 15,27 Jugular vein to both the car...…”